Oren Livne

Biography

Oren Livne co-chairs the Firm's North America Healthcare & Life Sciences Group and serves as a member of the Global Healthcare & Life Sciences Steering Committee. Before beginning his legal career, Oren co-founded a university technology transfer office and managed its licensing operations, which, together with his M.B.A, from New York University's Leonard N. Stern School of Business, provide a unique business perspective that he leverages for the benefit of the Firm's clients.

Practice Focus

Oren Livne counsels life sciences clients on a variety of corporate and transactional matters globally, including licensing and collaboration, mergers and acquisitions, spin outs, development funding, commercial contracts, and other intellectual property focused transactions.

Representative Legal Matters

Bayer in its acquisition of Perfuse Therapeutics for up to USD 2.45 billion including USD 300 million upfront and additional development, regulatory and commercial milestone payments based on success criteria.
Innovative Molecules on its strategic partnership with Alfasigma covering the parenteral formulation of adibelivir for the treatment of herpes simplex virus encephalitis, including payments of up to EUR 125 million in upfront and milestone payments.
icometrix, a Belgian-based leader in AI-powered medical imaging, in its sale to GE Healthcare.
Bristol-Myers Squibb on the transfer of Juno Therapeutics GmbH to TQ Therapeutics GmbH.
Galapagos in the planned creation of a new company with approximately EUR 2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions and amendment of its 10-year global Option, License and Collaboration Agreement with Gilead.
L'Oréal in its partnership with NanoEntek related to technology used in L'Oréal Cell BioPrint, a tabletop hardware device that provides personalized skin analysis.
BMS in its research collaboration and option agreement with AI Proteins for miniprotein-based therapeutics valued up to USD 400 million.
Astellas in its exclusive option and license agreement with AviadoBio for an investigational gene therapy targeting frontotemporal dementia, including a USD 20 million equity investment and up to USD 30 million in option exercise payments, plus the potential for USD 2.18 billion in license fees and milestone payments plus royalties if Astellas exercises its option.
Abbott in its global partnership to connect its continuous glucose monitoring system with Medtronic’s insulin delivery devices.
Astellas in its Research Collaboration and License Agreement with Elpiscience for novel bispecific macrophage engagers, including up to USD 37 million in upfront and option fees and potentially more than USD 1.7 billion in future development, regulatory, and commercial milestones.
Galapagos on the intended transfer of its Jyseleca® business to Alfasigma, including the European and UK Marketing Authorizations, the commercial, medical and development activities for Jyseleca® and approximately 400 FTEs in 14 European countries.
Astellas in its license agreement with 4D Molecular Therapeutics for the use of 4D's proprietary R100 vector for rare ophthalmic targets, including USD 20 million upfront and potential future option fees and milestones of up to USD 942.5 million.

Professional Honors

Band 1, Life Sciences, New Jersey, Chambers USA, 2025, 2026
Shortlisted for Licensing & Collaboration Attorney of the Year, LMG Life Sciences, 2023, 2024, 2025
Recommended for Transactions, IAM Patent 1000, 2024, 2025, 2026
Leading Life Sciences Lawyer, Licensing & Collaboration, LMG Life Sciences, 2022, 2023, 2024, 2025
LES Deal of Distinction™ Award for Life Sciences in 2023 for the Astellas - Cullgen strategic collaboration and option agreement
Rising Star, Super Lawyers New Jersey, 2020-2022
Shortlisted for Innovative Lawyers Award Asia-Pacific, Practice of Law - Healthcare, to Baker McKenzie Healthcare & Life Sciences Group on COVID-19 Response, FT 2021
IFLR Europe M&A Deal of the Year 2020, European Lifestars Deal of the Year 2019 (> GBP 500 million), and Best M&A Award Large-Cap Corporate Deal 2019 (Belgium) for the Galapagos - Gilead collaboration
Dealmakers Award to Baker McKenzie Life Sciences Group, NJLJ Professional Excellence, 2020
Notable Practitioner, IFLR 1000, 2020
Rising Star, Healthcare: Life Sciences, The Legal 500 United States, 2019
Certified Licensing Professional, 2008-2026

No aspect of this advertisement has been approved by the Supreme Court of New Jersey. Access a description of the selection methodology for the above awards.

Professional Associations and Memberships

New York State Bar Association
New Jersey State Bar Association
Licensing Executives Society

Admissions

New York~United States
New Jersey~United States
U.S. Patent and Trademark Office~United States

Education

New York University (MBA, with distinction) (2012)
New York University School of Law (JD) (2012)
Rutgers University (BS Biochemical Engineering, with Highest Honors) (1996)

Languages

English

Moderator, "Closing Deals in Uncertain Times," Bio International Convention, San Diego, June 22, 2026
Panelist, "Enhancing Innovation for CROs, CDMOs & Pharma," Research Triangle - North Carolina, December 2, 2025
Panelist, "Masterclass: Licensing & Partnering," LSX Investival Showcase, London, November 17, 2025
Moderator, "Platform Licensing: Biotech and Pharma Perspectives," Bio International Convention, Boston, June 16, 2025
Panelist, "Navigating the future: Life sciences deal-making amid geopolitical headwinds," Swiss Biotech Day, Basel, May 5, 2025
Co-author, "The U.S. BIOSECURE Act and Its Implications," Life Science Recht, November 18, 2024

Panelist, "Masterclass: Licensing & Partnering," LSX Investival Showcase, London, November 2024
Co-author, "The BIOSECURE Act: Potential Implications for Biotechnology Collaborations with Chinese Companies," Baker McKenzie's Global Sanctions and Export Control Blog, June 4, 2024
Moderator, "Creative Structures for Keeping Innovation Alive After the Deal," Bio International Convention, San Diego, June 2024
Presenter, "Masterclass: Licensing & Partnering," LSX Investival Showcase, London, November 2023
Panelist, "Diversifying Funding Sources: Founders’ Perspectives," Boston Life Sciences Showcase, September 28, 2023
Moderator and Panelist, "Life Sciences Industry: An update on the global legal landscape," Association of Corporate Counsel, September 13, 2023
Author, "Life sciences licensing from US universities – six areas to consider," ILO Healthcare & Life Sciences Newsletter, January 25, 2023
Presenter, "Masterclass: Moving up the value chain: Out-licensing and collaboration agreement tactics," LSX Investival Showcase, November 2022
Author, "Life Sciences Collaboration and Licence Agreements: Planning for Divorce," ILO Healthcare & Life Sciences Newsletter, January 19, 2022
Presenter, "Masterclass: Partnering & Licensing," LSX Investival Showcase, November 2021
Author, "Perfect Partners: How Pharma and Biotech Can Get the Best Out of Licensing and Collaborations," Intellectual Property Magazine, April 2020
Author, "Secondary Markets for Private Company Shares: Marketplace Overview and Predictive Capability," Glucksman Fellowship Program Student Research Reports, April 2012
Author, "A Cost Conscious Approach to Patent Application Filings," les Nouvelles, Journal of the Licensing Executives Society, Vol. 41, No.2, pp. 115-119, June 2006 (reprinted in 2007 in modified form in Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices)
Author, "Valuing and Monetizing IP Using Existing Organizational Structures," les Nouvelles, Journal of the Licensing Executives Society, Vol. 39, No.1, pp. 9-15, March 2004
Contributor, "Resource Manual for Bioprospecting," Public Interest Intellectual Property Advisors (PIIPA) Web Resource, October 2004 (updated in 2013)
Author, "Investigation of At-Risk Patent Filings," Journal of the Association of University Technology Managers, Vol. 14, pp. 19-29, 2002 (reprinted in the October 2003 issue of Industry and Higher Education)